【摘要】 目的研究肾移植受者口服多剂霉酚酸酯(MMF)后霉酚酸(MPA)的药代动力学特征。方法24例肾移植受者分为2组,口服MMF1.5g/d,于术后第7d、14d检测服药后不同时点静脉血MPA浓度,计算药动学参数。结果术后第7d、14dMPA峰浓度Cmax分别为(12.3±5.7)和(12.3±5.4)μg/ml(p>0.05);谷浓度C0分别为(0.7±0.5)和(1.8±1.0)μg/ml(P<0.05);Tmax分别为(1.5±0.9)和(1.3±0.6)h(P>0.05);AUC0-12h分别为(27.0±10.1)和(39.8±16.4)μg.h/ml(P<0.05);MRT0-12h分别为(3.2±0.8)和(4.0±0.6)h(P<0.05)。结论肾移植受者口服多剂MMF后,MPA在体内存在明显蓄积现象,需要对MPA进行血药浓度监测。更多还原

【Abstract】 Objective To study pharmacokinetics of mycophenolic acid (MPA) after Mycophenolate mofetil (MMF) was administered in mulpital oral dose in renal transplantation recipients.Methods 24 first renal allograft recipients were divided into 2 groups. All received a triple immunosuppressive regimen of MMF,cyclosporine (CsA) and corticosteroids. 9 samples of serum were drawn at the day 7 and day 14 after transplantation. MPA concentration was determined by HPLC and MPA pharmacokinetic parameters were calculated. Results The main pharmacokinetic parameters of MPA at the day 7 and day 14 after transplantation were as follows: Cmax were (12.3±5.7) and (12.3±5.4)μg/ml (P>0.05);C0 were (0.7±0.5) and (1.8±1.0)μg/ml (P<0.05);Tmax were (1.5±0.9) and (1.3±0.6) h (P>0.05);AUC0-12h were (27.0±10.1) and (39.8±16.4) μg·h/ml (P<0.05);MRT0-12h were (3.2±0.8) and (4.0±0.6)h (P<0.05). Conclusion: The accumulation for MPA after MMF administered in multiple oral dose in renal transplantation recipients was detected. MPA plasma concentration should be monitored in clinical practice.更多还原